Spruce Biosciences (NASDAQ:SPRB – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06, Zacks reports. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $1.80 million. Spruce Biosciences had a negative return on equity of 59.94% and a negative net margin of 450.38%.
Spruce Biosciences Stock Performance
Shares of SPRB traded down $0.01 during mid-day trading on Tuesday, hitting $0.53. 149,800 shares of the company’s stock were exchanged, compared to its average volume of 693,045. Spruce Biosciences has a 52 week low of $0.41 and a 52 week high of $5.95. The stock’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.56. The firm has a market cap of $21.72 million, a price-to-earnings ratio of -0.51 and a beta of 2.36. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.02.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on SPRB. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 target price on shares of Spruce Biosciences in a research note on Tuesday. HC Wainwright reiterated a “neutral” rating on shares of Spruce Biosciences in a research note on Monday, August 19th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $5.00.
Spruce Biosciences Company Profile
Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.
Read More
- Five stocks we like better than Spruce Biosciences
- What is a Special Dividend?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- How to Use the MarketBeat Stock Screener
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- 5 discounted opportunities for dividend growth investors
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.